3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
20
Carcinoma, Renal Cell
10
Neuroendocrine Tumors
7
Neoplasm Metastasis
7
Recurrence
4
Tuberous Sclerosis
3
Triple Negative Breast Neoplasms
3
Neoplasms
3
Kidney Neoplasms
3
Endometrial Neoplasms
3
von Hippel-Lindau Disease
2
Skin Neoplasms
2
Sarcoma
2
Meningioma
2
Glioma
2
Gastro-enteropancreatic neuroendocrine tumor
2
Diffuse Intrinsic Pontine Glioma
2
Carcinoma, Hepatocellular
2
Adenoma, Islet Cell
2
Waldenstrom Macroglobulinemia
1
Vascular Malformations
1
Unilateral Breast Neoplasms
1
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Thymus Neoplasms
1
Seizures
1
Sarcoma, Kaposi
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Interventions
Letrozole
5
Fulvestrant
5
trastuzumab deruxtecan
3
Injections
3
toripalimab
2
sacituzumab govitecan
2
palbociclib
2
elacestrant
2
abemaciclib
2
Anastrozole
2
AZD9833
2
ribociclib
1
pyrotinib
1
exemestane
1
eribulin
1
disitamab vedotin
1
dalpiciclib
1
Vinorelbine
1
Selective Estrogen Receptor Modulators
1
Ritonavir
1
RAD1901
1
Paclitaxel
1
Lead
1
Itraconazole
1
Goserelin
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Docetaxel
1
Bevacizumab
1
Aromatase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Breast Cancer
×
Everolimus
×
1 year
×
Clear all
NCT06382948
2026-04-03
ADELA
MedSIR
Phase 3
Recruiting
240 enrolled